RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 1

Registered title, quoted from ClinicalTrials.gov

Mts105 for Advanced Hepatocellular Carcinoma

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Peking University Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Peking University Cancer Hospital北京大学肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06689540, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC), excluding fibrolamellar or sarcomatoid subtypes, as well as mixed hepato-cholangiocellular carcinoma;

    Inclusion criterion 1

  3. Child-Pugh Score ≤ 6

    Inclusion criterion 6

  4. Received any investigational drug within 4 weeks prior to the first dose.

    Exclusion criterion 4

    Received localized therapy for hepatocellular carcinoma (HCC), including but not limited to arterial chemoembolization (TACE), arterial infusion chemotherapy (HAIC), Y-90 radioembolization, ablative therapy, or stereotactic radiation therapy (SBRT), within 4 weeks prior to the first dose.

    Exclusion criterion 5

    Received other anticancer therapies, such as multi-targeted tyrosine kinase inhibitors (mTKIs) and/or anti-VEGF therapies, within 3 weeks.

    Exclusion criterion 6

    Received non-specific immunomodulatory therapy, including but not limited to interleukin, interferon, thymidine, etc., within 2 weeks prior to the first dose.

    Exclusion criterion 7

    Unresolved toxicity from prior anticancer therapy (> grade 1, according to CTCAE v5.0).

    Exclusion criterion 11

  5. ECOG score ≤ 1

    Inclusion criterion 7

  6. Hematology: No blood transfusion or colony-stimulating factor therapy within 7 days prior to the first dose. The following hematological parameters should be met:Absolute neutrophil count ≥ 1.5 × 10\^9/L;Lymphocyte count ≥ 0.5 × 10\^9/L;Hemoglobin ≥ 90 g/L;Platelet count ≥ 75 × 10\^9/L;

    Inclusion criterion 9

    Liver function:Total bilirubin ≤ 2.5 mg/dL;Albumin ≥ 28 g/L;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN;

    Inclusion criterion 10

    Renal function:Serum creatinine ≤ 1.5 × ULN, or endogenous creatinine clearance ≥ 45 mL/min (as determined by the CKD-EPI formula);Urinary protein < 2+, or urinary protein ≥ 2+ but with 24-hour protein quantification ≤ 1.0 g

    Inclusion criterion 12

  7. Presence of a measurable tumor lesion (per RECIST/ mRECIST criteria).

    Inclusion criterion 4

  8. For HBV-associated HCC:

    Exclusion criterion 17

    HBsAg (+) : less than 2 weeks of HBV antiviral standard treatment before the first administration of study drug, with an HBV DNA viral load ≥ 1000 IU/mL.

    Exclusion criterion 18

    HBcAb (+) , HBsAg (-): HBV DNA viral load ≥ 1000 IU/mL.

    Exclusion criterion 19

    Hepatitis C virus-infected subjects who have not completed 4 weeks of antiviral treatment.

    Exclusion criterion 20

    Positive for human immunodeficiency virus (HIV+).

    Exclusion criterion 21

  9. Women who are pregnant or breastfeeding.

    Exclusion criterion 25

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06689540, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC), excluding fibrolamellar or sarcomatoid subtypes, as well as mixed hepato-cholangiocellular carcinoma;
  • Positive for GPC3 expression per immunohistochemical (IHC) staining.
  • Failure of standard systemic therapies, including at least one immune checkpoint inhibitor and one targeted therapy (Tyrosine Kinase Inhibitors, and/or anti vascular endothelial growth factor agent).
  • Presence of a measurable tumor lesion (per RECIST/ mRECIST criteria).
  • Barcelona Clinical Liver Cancer Stage B or C (BCLC B/C)
  • Child-Pugh Score ≤ 6
  • ECOG score ≤ 1
  • Adequate organ and bone marrow function as defined by the following laboratory criteria:
  • Hematology: No blood transfusion or colony-stimulating factor therapy within 7 days prior to the first dose. The following hematological parameters should be met:Absolute neutrophil count ≥ 1.5 × 10\^9/L;Lymphocyte count ≥ 0.5 × 10\^9/L;Hemoglobin ≥ 90 g/L;Platelet count ≥ 75 × 10\^9/L;
  • Liver function:Total bilirubin ≤ 2.5 mg/dL;Albumin ≥ 28 g/L;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN;
  • International Normalized Ratio (INR) ≤ 2.3;Oral anticoagulant therapy at a stable dose for at least 2 weeks. If oral warfarin is used, the patient must have an INR ≤ 3.0 and no bleeding events within 28 days prior to administration;
  • Renal function:Serum creatinine ≤ 1.5 × ULN, or endogenous creatinine clearance ≥ 45 mL/min (as determined by the CKD-EPI formula);Urinary protein < 2+, or urinary protein ≥ 2+ but with 24-hour protein quantification ≤ 1.0 g
  • Cardiac function:Left ventricular ejection fraction (LVEF) ≥ 50%; No clinically significant abnormal ECG findings (chronic atrial fibrillation is allowed, provided it does not require medication);
  • Capable of full communication with the investigator, with the ability to understand and comply with study requirements, and able to understand and sign the informed consent form (ICF).
  • ≥18 years

Exclusion Criteria:

  • Any known active intracranial metastases, or brain metastases that have been treated for less than 4 weeks.
  • Recent Antitumor Therapy:
  • Treatment with any immune checkpoint inhibitor within 4 weeks (28 days) prior to the first dose.
  • Received any investigational drug within 4 weeks prior to the first dose.
  • Received localized therapy for hepatocellular carcinoma (HCC), including but not limited to arterial chemoembolization (TACE), arterial infusion chemotherapy (HAIC), Y-90 radioembolization, ablative therapy, or stereotactic radiation therapy (SBRT), within 4 weeks prior to the first dose.
  • Received other anticancer therapies, such as multi-targeted tyrosine kinase inhibitors (mTKIs) and/or anti-VEGF therapies, within 3 weeks.
  • Received non-specific immunomodulatory therapy, including but not limited to interleukin, interferon, thymidine, etc., within 2 weeks prior to the first dose.
  • Received herbal or proprietary Chinese medicine for antitumor indications within 1 week prior to the first dose.
  • Previously received experimental treatment targeting GPC3 (patients may be enrolled if they remain positive for GPC3 upon testing).
  • History of liver transplantation or hematopoietic stem cell transplantation.
  • Unresolved toxicity from prior anticancer therapy (> grade 1, according to CTCAE v5.0).
  • Major surgery (other than biopsy) within 28 days prior to the first dose.
  • Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg).
  • Class III-IV heart failure by New York Heart Association (NYHA) criteria within 6 months prior to the first dose, unstable angina, myocardial infarction, bypass surgery, stent placement, cerebral infarction, or clinically significant valvular heart disease.
  • QTcF ≥ 450 ms in men and ≥ 470 ms in women (by Fridericia formula).
  • Severe infection within 4 weeks before the first dose (excluding viral hepatitis), or any signs or symptoms of active infection within 2 weeks before the first dose, or patients requiring antibiotic treatment within 2 weeks (excluding local medications and prophylactic antibiotics); unexplained fever > 38.5°C before the first dose.
  • For HBV-associated HCC:
  • HBsAg (+) : less than 2 weeks of HBV antiviral standard treatment before the first administration of study drug, with an HBV DNA viral load ≥ 1000 IU/mL.
  • HBcAb (+) , HBsAg (-): HBV DNA viral load ≥ 1000 IU/mL.
  • Hepatitis C virus-infected subjects who have not completed 4 weeks of antiviral treatment.
  • Positive for human immunodeficiency virus (HIV+).
  • Subjects requiring systemic corticosteroids (equivalent dose of prednisone > 10 mg/day) or other immunosuppressive drugs within 14 days prior to the first dose or during the study.
  • History of autoimmune disease requiring systemic treatment within 2 years prior to the first dose.
  • History of other malignancies within 2 years prior to the first dose (excluding cured skin basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ, breast ductal carcinoma in situ, or other cancers that the investigator believes are cured and have an extremely low risk of recurrence).
  • Women who are pregnant or breastfeeding.
  • Any other condition that, in the opinion of the investigator, makes participation in the study inappropriate.

Quoted from ClinicalTrials.gov, NCT06689540, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06689540, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06689540